Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05351268
Other study ID # BYSY-2022-3DPCT-TC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date April 30, 2026

Study information

Verified date December 2023
Source Peking University Third Hospital
Contact Zhe Ji, M.D.
Phone 008618710002823
Email aschoff@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main technical difficulties in radioactive iodine-125 seed implantation (RISI) lie in the complexity of operation and the control of operation quality. The current data shows that under the combined guidance of 3D-printing template and CT, the accuracy of RISI has been significantly improved, and the actual target dose could meet the design requirements of preoperative plan. At present, 3D printing templates (3DPT) are divided into non-coplanar templates (3DPNCT) and coplanar templates (3DPCT). In clinical practice, due to the complex technical requirements, high production cost and long printing time of 3DPNCT, a considerable number of patients can also complete the treatment with 3DPCT. Moreover, compared with 3DPNCT, 3DPCT has the advantages of accurate needle path control, fast needle path adjustment, convenient for intraoperative real-time optimization, without waiting for printing time, easy for doctors to master, lower cost than 3DPNCT, and easy to carry out at the grass-roots level. Therefore, this study intends to explore 3DPCT technology to further clarify: (1) the accuracy of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors; (2) the short-term efficacy and toxicity of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 30, 2026
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm. - There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment. - No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment. - No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found. - There is a suitable puncture path, and the therapeutic dose is expected to be achieved. - KPS > 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months. Exclusion Criteria: - Severe impairment of lung function (such as FEV1 < 40% predicted value, FVC < 50% predicted value, DLCO < 40% predicted value). - High risk of skin invasion and ulceration at the puncture site before treatment. - There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor. - Pregnant women, lactating women and mentally ill patients. - The patient with poor compliance and unable to complete the treatment. - Other conditions of the researchers who think it is not suitable to participate in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radioactive seed brachytherapy
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.

Locations

Country Name City State
China Peking University Third Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local progression free survival The time from the date of SBRT to the date of local recurrence or death or the date of last observation. From the beginning of the treatment to 2 years after the treatment.
Primary Incidence of adverse events The adverse events are evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event will be measured. From the beginning of the treatment to 2 years after the treatment.
Secondary Overall survival The time from the date of seeds implantation to the date of death from any cause or the date of last observation. From the beginning of the treatment to 2 years after the treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT04837950 - Changes in Pleural Cavity Volume and Surgical Exposure N/A
Completed NCT03121287 - Early Imaging Biomarkers in NSCLC
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Recruiting NCT05053230 - A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer N/A
Completed NCT04570722 - Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study) N/A
Completed NCT05459311 - Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR)
Completed NCT01833637 - Electronic Patient Reported Symptom Assessment N/A
Completed NCT03676426 - Comparison of a Web-based Advance Directive to a Standard Advance Directive N/A
Completed NCT03658083 - Exploring Robotic-assisted Thoracic Surgery for Lung Cancer
Recruiting NCT05063396 - OFA in Thoracic Surgery N/A
Recruiting NCT03804307 - Short Course Radiation Therapy in Palliative Treatment of Thoracic Cancer N/A
Enrolling by invitation NCT05629065 - Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC) N/A
Recruiting NCT04749212 - Perioperative Troponin I and NT Pro-BNP in Lung Resection
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Recruiting NCT05502263 - Interest of CPET to Predict Mortality and Complications of Lung Resection Candidates
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Recruiting NCT06342284 - Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer
Recruiting NCT04799561 - Teleprehabilitation for Surgical Cancer Patients N/A
Completed NCT05143541 - Use of a New Stapling Device in General Thoracic Surgery
Active, not recruiting NCT04686500 - VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors N/A